We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Of Its Kind Measles Antibody Test Validated for Use with Dried Blood Spot Samples

By LabMedica International staff writers
Posted on 04 Mar 2025
Print article
Image: The Anti-Measles Virus ELISA 2.0 (IgG) has received CE Mark (Photo courtesy of AdobeStock)
Image: The Anti-Measles Virus ELISA 2.0 (IgG) has received CE Mark (Photo courtesy of AdobeStock)

Measles is a highly contagious airborne disease that can lead to serious complications for those infected. With the number of measles cases increasing worldwide, expanding and improving access to testing for the measles virus is crucial for enhancing surveillance and prevention efforts. Now, a novel assay supports the diagnosis of a measles virus infection and also determines the immune status against measles virus, with validation for dried blood spots (DBS) as well as serum and plasma samples.

Revvity, Inc. (Waltham, MA, USA) has launched EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG), designed to assist in diagnosing measles virus infections or determining immunity to the virus. The Anti-Measles Virus ELISA 2.0 (IgG) is the first in a series of assays being developed by EUROIMMUN to expand its portfolio of serological infection diagnostics, now including validation for DBS in addition to serum and plasma. The use of DBS in diagnostics only requires a few drops of capillary blood to produce reliable test results. The blood is typically obtained from the fingertip, placed on a paper card, and then sent to a diagnostic lab for analysis.

The minimally invasive sampling method and the high stability of DBS make this diagnostic approach advantageous for routine testing, research studies, or in areas with limited medical infrastructure. By enabling the use of DBS rather than traditional venous blood samples, this innovation increases accessibility for healthcare practitioners and diagnostic labs investigating measles virus infections. The Anti-Measles Virus ELISA 2.0 (IgG) can be processed either manually or automatically with EUROIMMUN’s scalable solutions designed for DBS processing and ELISA.

“Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution,” said Dr. Lars Komorowski, chief scientific officer of EUROIMMUN.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.